Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;27(3):383-391.
doi: 10.1111/hae.14318. Epub 2021 Apr 23.

Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring

Assaf A Barg  1   2 , Ivan Budnik  3 , Einat Avishai  1   2 , Tami Brutman-Barazani  1   2 , Dalia Bashari  1 , Mudi Misgav  1 , Aaron Lubetsky  1 , Amir A Kuperman  4   5 , Tami Livnat  1   2 , Gili Kenet  1   2
Affiliations

Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring

Assaf A Barg et al. Haemophilia. 2021 May.

Abstract

Introduction: Real-world data on prophylaxis of severe haemophilia A (HA) patients treated by emicizumab are scarce.

Aim: To study the efficacy and safety of longitudinal emicizumab prophylaxis and assess laboratory monitoring correlations in a large patient cohort.

Methods: HA patients with and without FVIII inhibitors, initiating emicizumab prophylaxis, were prospectively enrolled. Bleeding, adverse events and surgeries were documented. FVIII inhibitors, emicizumab levels and thrombin generation (TG) were sequentially measured.

Results: A total of 107 patients, including 58 children (whose median (IQR) age was 6 (1-11) years) with severe HA, composed the study cohort. Twenty-nine per cent (31/107) of our HA patients had FVIII inhibitors. Patients were followed for a median of 67 weeks (up to 144 weeks). Fifty-three patients, whose median follow-up was 53 weeks, experienced zero bleeds. Most bleeds (94%) among children were trauma-related, whereas 61% of adults sustained spontaneous joint bleeds. Four patients experienced major bleeds, with a fatal outcome in one infant, who also presented with central venous line thrombosis. No other serious adverse events were encountered. Seven patients have decided to stop emicizumab treatment for various reasons. Emicizumab plasma levels increased after emicizumab prophylaxis initiation, and values were maintained during follow-up, in all but one patient, suspected of anti-drug antibodies. A significant reduction of FVIII inhibitor levels was noted among inhibitor patients. TG was increased and sustained yet could not prognosticate bleeding risk.

Conclusion: Emicizumab prophylaxis was mostly well tolerated, although 50% of patients experienced breakthrough bleeds. Routine TG monitoring is not obligatory, and further studies are warranted in selected patient populations.

Keywords: bleeding; emicizumab; haemophilia; monitoring; thrombin generation; thrombosis.

PubMed Disclaimer

References

REFERENCES

    1. Manco-Johnson MJ, Soucie JM, Gill JC; Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368-2374.
    1. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in Hemophilia. Blood. 2014;124(23):3365-3372.
    1. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia. 2010;16(Suppl. 1):20-24.
    1. Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia. 2013;19:2-7.
    1. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463-2468.

Grants and funding

LinkOut - more resources